Celldex Therapeutics, Inc. (CLDX)

32.02 +1.81 (+5.99%) At close: 04:00PM EST

Celldex Therapeutics, Inc.

Perryville III Building
Suite 220 53 Frontage Road
Hampton, NJ 08827
United States
908 200 7500
https://www.celldex.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 148

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Anthony S. Marucci M.B.A.	Founder, President, CEO & Director	1.14M	3.91M	1962
Dr. Tibor Keler	Founder, Chief Scientific Officer & Executive VP	739.03k	575.74k	1959
Mr. Sam Martin	Senior VP, CFO, Secretary & Treasurer	617.26k	634.9k	1971
Dr. Margo Heath-Chiozzi M.D.	Senior Vice President of Regulatory Affairs	614.12k	N/A	1957
Dr. Diane C. Young M.D.	Senior VP & Chief Medical Officer	643.5k	2.04M	1957
Prof. Joseph P. Schlessinger Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1945
Ms. Sarah Cavanaugh	Senior Vice President of Corporate Affairs & Administration	N/A	N/A	1975
Patrick Till	Senior Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Freddy A. Jimenez Esq.	Senior VP & General Counsel	579.7k	N/A	1969
Dr. Ronald A. Pepin	Chief Business Officer & Senior VP	441.84k	N/A	1956

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Corporate Governance

Celldex Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2023 is 1. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.